In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes.
Level 5 - mechanism / opinion, no new human data
Preclinical animal research (in vivo mouse model)
PubMed 22522929 · doi:10.1038/nature11044
What was done
Researchers used genetic lineage tracing in a mouse model of myocardial infarction induced by coronary ligation to evaluate whether local delivery of three transcription factors—Gata4, Mef2c, and Tbx5 (GMT)—could directly reprogram resident cardiac non-myocytes into cardiomyocytes in vivo. They assessed cellular morphology, gene expression, single-cell electrophysiology, infarct size, and cardiac function up to 3 months post-infarction, with and without co-administration of thymosin beta 4.
What was found
Delivery of GMT reprogrammed resident non-myocytes into cells that were binucleate, assembled sarcomeres, expressed cardiomyocyte-like genes, demonstrated ventricular cardiomyocyte-like action potentials, showed electrical coupling, and contracted upon electrical stimulation. GMT delivery decreased infarct size and modestly attenuated cardiac dysfunction over 3 months, with additional improvements in scar size and function observed when combined with thymosin beta 4. The abstract reports no numerical values, confidence intervals, or sample sizes.
Why it matters
This study provides proof-of-concept that resident cardiac fibroblasts can be directly converted into functional cardiomyocyte-like cells in their native heart environment, suggesting a direct reprogramming strategy for post-infarction regenerative therapy.
Limits
The study was conducted entirely in mice, which may not translate directly to human cardiac physiology or scale. The abstract does not report sample sizes, quantitative effect sizes, conversion efficiencies, or potential arrhythmogenic risks.
Cited by
- supports Deepak Srivastava used gene therapy to convert cardiac fibroblasts into myocytes after heart attack damage.